SCHEMBL12247293

SCHEMBL12247293

CC1(C)c2ccccc2-c2cc3c(-c4cccc(-c5nc6ccccc6n5-c5ccccc5)c4)c4ccccc4c(-c4ccc(-c5ccccn5)nc4)c3cc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.35
HDAC8 Q9BY41 3/20 0.35
HDAC6 Q9UBN7 3/20 0.35
PTGER4 P35408 1/20 0.34
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
ATR Q13535 1/20 0.33
RECQL P46063 1/20 0.32
CTSD P07339 1/20 0.32
MAPK10 P53779 2/20 0.32
HRH3 Q9Y5N1 1/20 0.32
ALOX5AP P20292 1/20 0.31
POLB P06746 2/20 0.31
ALDH1A1 P00352 2/20 0.31
RXFP1 Q9HBX9 1/20 0.31
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
MEN1 O00255 1/20 0.30
HSP90AA1 P07900 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12247296 1.00 HDAC1 (0.35) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247297 0.94 ESR1 (0.35) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247289 0.94 ESR1 (0.35) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247180 0.90 ESR1 (0.39) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247183 0.90 ESR1 (0.39) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12246966 0.89 ESR1 (0.39) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247295 0.89 ESR1 (0.41) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247182 0.88 ESR1 (0.39) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247166 0.88 ESR1 (0.39) HDAC1HDAC8HDAC6PTGER4ESR1
SCHEMBL12247291 0.88 ESR1 (0.42) HDAC1HDAC8HDAC6PTGER4ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME KCNJ2, KCNJ1, BRD4 HDAC1 1225/4885HDAC8 986/4885HDAC6 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.